1. The safety of rituximab in hepatitis C virus (HCV) positive patients.
- Author
-
Pérez-Calvo J, Murashige N, Fuertes M, Kikuchi D, Benito R, Kusumi E, Kami M, and Taniguchi S
- Abstract
Background: The extrahepatic manifestations of HCV infection are usually refractory to IFN-alpha and ribavirin. Given that the pathophysiology is autoimmune disorders, rather than the direct cytotoxicity of HCV, various immunosuppressants have been attempted, including rituximab with favorable results. However, questions on the possible opportunistic infections and hepatitis exacerbation by rituximab remain unsolved.Methods: We hereby report 8 HCV-positive cases treated with rituximab. Indication for the treatment were severe extrahepatic conditions associated with HCV infection in 2 cases and malignant lymphoma in 6. Sequential measurements of serum transaminases, viral load, and routine clinical examination were performed for a median follow-up of 13 months.Results: None of the 8 patients showed clinical or liver deterioration, or opportunistic infections, although 3 of them had a significant increase in HCV-load. Rituximab was well tolerated in all cases.Conclusions: Our results further support the safety of rituximab in HCV-positive patients, providing a promising treatment modality, when needed, for HCV-associated extrahepatic disorders. [ABSTRACT FROM AUTHOR]
- Published
- 2004